THE CHROMOSOME | Clinical Content Series
Hypothyroidism
Back to Case Studies ArchiveCase Study
She was 38 years old and had gained 28 kilograms over four years without changing anything about the way she ate or lived. She was exhausted in a way she could not explain, not tired from activity but heavy in a deeper sense, as though her body was running on a fraction of the power it once had. Her hair was thinning. Her skin was dry. She was cold when everyone around her was warm. She had been told it was stress. She had been told it was age. She had been told, more than once, that these things happen to women in their thirties.
Nobody had looked at her thyroid.
When I examined her and reviewed her bloods, her TSH was significantly elevated and her free T4 was at the floor of the normal range, a pattern I have seen hundreds of times in Pakistani women presenting with unexplained weight gain. Her thyroid was producing insufficient hormone to meet her body's metabolic demands, and her metabolism had responded the only way it knows how, by slowing down. Every system in her body was running below capacity. Her heart rate was low. Her gut motility was reduced. Her ability to generate heat and burn calories had fallen to a fraction of what it should have been.
What made her case particularly important was the question I asked that her previous physicians had not. Was the hypothyroidism the cause of the obesity, or had the obesity contributed to the thyroid dysfunction? In her case the answer was both. She had a genetic predisposition to thyroid underfunction that had been present long before the weight arrived, and the weight, once established, had deepened the dysfunction through the inflammatory pathway that visceral fat creates.
This dual relationship is something I see consistently in Pakistani patients. The thyroid and obesity do not merely coexist. They drive each other. And until both are treated simultaneously, neither resolves.
We treated her thyroid. We treated her metabolic rate. We treated her visceral fat and the inflammation it was generating. Sixteen months later she had lost 23 kilograms and her TSH had normalised without dose escalation for the first time since her diagnosis.
The thyroid was never the whole story. But it was always part of it.
FAQs
Hypothyroidism occurs when the thyroid gland produces insufficient hormone to meet the body's metabolic demands. Every cell in the body depends on thyroid hormone to regulate its energy use, when supply falls short, metabolism slows across every organ system simultaneously. Pakistani women are disproportionately affected due to a combination of iodine insufficiency in certain regions, autoimmune predisposition, and the FTO gene's influence on the hypothalamic pituitary thyroid axis. Dr. Zaar consistently identifies hypothyroidism as both a primary driver of weight gain and a secondary consequence of visceral obesity, a dual relationship that Pakistani medicine rarely treats as the unified condition it actually is.
Thyroid hormone governs the rate at which every cell in the body converts nutrients into energy. When thyroid output falls, this conversion slows, the body burns fewer calories at rest, generates less heat, moves food through the gut more slowly, and stores a greater proportion of every meal as fat. Patients do not gain weight because they are eating more. They gain weight because their body has become metabolically less capable of processing what they eat. This distinction is critical and consistently missed in Pakistani clinical practice, where hypothyroid weight gain is still frequently attributed to diet rather than to the hormonal failure driving it.
The FTO gene at Chromosome 16q12.2 influences hypothalamic regulation of the entire endocrine system, including the signals that govern thyroid stimulating hormone production and release. In Pakistani patients, this genetic influence creates a predisposition to thyroid axis dysregulation that manifests earlier and more severely than in Western populations. Dr. Zaar's clinical experience shows that Pakistani patients with the FTO associated metabolic profile frequently present with thyroid dysfunction at TSH levels that Western reference ranges classify as borderline, levels at which Pakistani patients are already experiencing significant metabolic consequences that go untreated.
Both directions of this relationship are clinically real and both operate simultaneously in a significant proportion of Pakistani patients. Hypothyroidism slows metabolism and drives fat accumulation directly. But the visceral fat that accumulates then releases inflammatory cytokines that suppress thyroid receptor function at the cellular level, meaning the body becomes less capable of using whatever thyroid hormone is available, even when levels are medically corrected. This is why many Pakistani patients on thyroid replacement therapy continue to gain weight or fail to lose it. The medication addresses the hormone level. It does not address the inflammatory environment that is blocking the hormone's action. THE CHROMOSOME protocol treats both simultaneously.
Because in many cases it is not, not because the dose is wrong, but because the medication is being asked to work in a hostile biological environment. Visceral fat generated inflammatory cytokines impair thyroid hormone receptor sensitivity at the cellular level, meaning that even normal circulating thyroid hormone cannot exert its full metabolic effect. Additionally, insulin resistance, highly prevalent in Pakistani patients, further suppresses thyroid conversion from the inactive T4 form to the active T3 form that cells actually use. Dr. Zaar's protocol addresses the entire thyroid hormone pathway, not merely the TSH number on a laboratory report.
The classic symptoms, fatigue, weight gain, cold intolerance, dry skin, hair thinning, constipation, and low mood, are well known but frequently attributed to other causes in Pakistani clinical practice. Less recognised is the cognitive slowing that patients describe as brain fog, the fluid retention that mimics simple weight gain, the menstrual irregularity that is dismissed as stress, and the muscle weakness that is attributed to a sedentary lifestyle. Dr. Zaar's 500 question diagnostic assessment captures the full clinical picture of thyroid dysfunction across all organ systems, because a TSH result alone tells only a fraction of the story.
Hypothyroidism rarely presents alone in the Pakistani obesity patient. It exists in a web of hormonal relationships that amplify its effects and complicate its treatment. Insulin resistance deepens thyroid hormone conversion failure. Elevated cortisol suppresses TSH production. Oestrogen dominance impairs thyroid hormone binding and transport. Leptin resistance disrupts the hypothalamic signals that govern thyroid axis activity. Each of these relationships is bidirectional, thyroid dysfunction worsens each of them in return. This is why treating hypothyroidism in isolation, as most Pakistani physicians do, produces incomplete results. THE CHROMOSOME protocol maps the entire hormonal network and treats it as the interconnected system it actually is.
Subclinical hypothyroidism, where TSH is mildly elevated but thyroid hormone levels remain technically within the normal range, is frequently dismissed as not requiring treatment in Pakistani clinical practice. For obese Pakistani patients this is a clinically significant error. At the metabolic level, even mildly elevated TSH is associated with impaired fat oxidation, worsening insulin resistance, elevated cholesterol, and progressive weight gain. In patients already carrying the metabolic burden of visceral obesity and FTO gene associated dysfunction, subclinical hypothyroidism acts as an accelerant, deepening every other hormonal disruption simultaneously. Dr. Zaar treats the patient, not the reference range.